‘What Happens Next’ – The 7th Acorn Regulatory Brexit Whitepaper

The seventh Acorn Regulatory Brexit whitepaper has just been published.  It looks at the impact of a no deal departure from the EU on a number of sectors.

Our pharmacovigilance team look at the measures that companies need to put in place now if they are to prepare for the UK leaving the EU without a deal.  The role of the QPPV has been much discussed in recent years, since the outcome of the referendum became known, and companies need to be aware of the implications that Brexit will have on that role.

The medical devices team look at the role of the EU Authorised Representative and the implications for Notified Bodies.  The devices sector is in a particular ‘state of flux’ at present with the introduction of new legislation and Brexit adds to the issues that device manufacturers need to be mindful of at this time.

Finally, our medical team look at the impact on clinical trials.  Trial sponsors and partners need to be aware of the impact of Brexit and the article contained in the whitepaper looks at what needs to be considered.

You can download the latest Acorn Regulatory Brexit whitepaper by completing the details below and we will send it straight to you.